Navigation Links
GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
Date:9/19/2013

LONDON, Sept. 20, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present a general company update at the 2013 Aegis Capital Healthcare Conference in Las Vegas, NV on Friday, September 27, 2013, at 9:00 a.m. PT (12:00 p.m. ET).

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and GWP42006 in Phase 1 clinical development for the treatment of epilepsy. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies
2. RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
3. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
4. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
5. Inovio Pharmaceuticals to Hold Investor Conference Call to Discuss Partnership with Roche
6. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
7. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
8. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
9. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
10. GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
11. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied ... that the global biometric technology market is expected to generate revenue of $10.72 billion ... Continue Reading ... Allied Market Research ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):